Search - tctmd.com

Displaying 121 - 140 of 537

Sort: Relevancy | Date

SAXOPHONE Bolsters Apixaban for Pediatric Heart Disease

News Daily News

SAXOPHONE Bolsters Apixaban for Pediatric Heart Disease

December 05, 2023

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

November 20, 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

November 13, 2023

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Presentation AHA 2023

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Presenter: Alexander C. Fanaroff

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

News Conference News HFSA 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

October 11, 2023

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

News Daily News

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

September 19, 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

News Conference News ESC 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

Michael O'Riordan

August 31, 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

August 30, 2023

With Focus on Stroke, Low-Dose Aspirin Still No Good for Primary Prevention

News Daily News

With Focus on Stroke, Low-Dose Aspirin Still No Good for Primary Prevention

July 26, 2023

Pitavastatin Cuts MACE in HIV-Infected Patients REPRIEVE

News Daily News

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

Michael O'Riordan

July 25, 2023

USPSTF: Screening Kids for Lipid Disorders Still Needs More Data

News Daily News

USPSTF: Screening Kids for Lipid Disorders Still Needs More Data

July 18, 2023

SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients

News Daily News

SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients

July 17, 2023

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

News Daily News

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Michael O'Riordan

July 11, 2023

Some Daylight for Vitamin D? New Analysis Hints at Small CVD Benefit

News Daily News

Some Daylight for Vitamin D? New Analysis Hints at Small CVD Benefit

Michael O'Riordan

June 30, 2023

Aspirin Use Ups Risk of Anemia in Elderly Patients: ASPREE

News Daily News

Aspirin Use Ups Risk of Anemia in Elderly Patients: ASPREE

Michael O'Riordan

June 22, 2023

Testosterone Doesn’t Cause CV Events in High-Risk Men With Hypogonadism

News Daily News

Testosterone Doesn’t Cause CV Events in High-Risk Men With Hypogonadism

June 16, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.